Formulation and in vitro Evaluation of Targeted Chemotherapy of Crizotinib-loaded polymeric Nanoparticles on Cancer Cell Lines

This nanotechnology approach offers a promising targeted drug delivery system for Crizotinib, characterized by small particle size, high encapsulation efficiency (EE), and optimal in vitro drug release.

Authors

Institutions

Publication Details

Journal
Current Pharmaceutical Design
Published
2025-08-18
DOI
https://doi.org/10.2174/0113816128412622250730015435
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Formulation and in vitro Evaluation of Targeted Chemotherapy of Crizotinib-loaded polymeric Nanoparticles on Cancer Cell Lines

Faiza Naureen, Reem M. Alnemari, Maqsood Ur Rehman, Yasar Shah
Current Pharmaceutical Design
Lung Cancer Treatments and Mutations
article

Formulation and in vitro Evaluation of Targeted Chemotherapy of Crizotinib-loaded polymeric Nanoparticles on Cancer Cell Lines

Faiza Naureen, Reem M. Alnemari, Maqsood Ur Rehman, Yasar Shah
article en

Abstract

This nanotechnology approach offers a promising targeted drug delivery system for Crizotinib, characterized by small particle size, high encapsulation efficiency (EE), and optimal in vitro drug release.

Current Pharmaceutical DesignVol. 32(13)
Taif University (SA), Abdul Wali Khan University Mardan (PK), University of Malakand (PK)
Good health and well-being
Openalex Percentile: Top 68%
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.